...2283 patients’ melanomas harbored a documented BRAF V600 mutation...Two hundred and ninety seven were found to have received treatment with front‐line BRAF/MEKi (n = 35 vemurafenib/cobimetinib, n = 262 dabrafenib/trametinib), while 162 patients received treatment with front‐line aPD‐1 (n = 69 nivolumab, n = 93 pembrolizumab), and 108 patients received treatment with front‐line niv/ipi....In our real-world retrospective analysis, patients with advanced BRAF mutant melanoma treated with front-line niv/ipi or aPD-1 had longer survival compared to those treated with front-line BRAF/MEKi.

We retrospectively collected data of Asian patients with advanced BRAF V600-mutant melanoma treated with first-line BRAF/MEK inhibitors (BRAF/MEKi), anti-PD-1 monotherapy (Anti-PD-1), and nivolumab plus ipilimumab (PD-1/CTLA-4)...For patients treated with BRAF/MEKi, anti-PD-1, PD-1/CTLA-4, the median ages at baseline were 62, 62, and 53 years (p = 0.03); objective response rates were 69%, 27%, and 28% (p < 0.001); median progression-free survival (PFS) was 14.7, 5.4, and 5.8 months (p = 0.003)...